BLAST PHASE MYELOPROLIFERATIVE NEOPLASM
Clinical trials for BLAST PHASE MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new BLAST PHASE MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for BLAST PHASE MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for rare blood cancer: new combo trial targets tough cases
Disease control Recruiting nowThis study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…
Matched conditions: BLAST PHASE MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:46 UTC
-
New combo may open door to transplant for advanced blood cancer patients
Disease control Recruiting nowThis study tests whether adding the drug pacritinib to standard chemotherapy (azacitidine or decitabine) can help more people with advanced myeloproliferative neoplasms (MPN) become eligible for a stem cell transplant. About 27 adults with accelerated or blast-phase MPN will rece…
Matched conditions: BLAST PHASE MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: BLAST PHASE MYELOPROLIFERATIVE NEOPLASM
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 08:31 UTC